Press "Enter" to skip to content

FDA provides update on its ongoing investigation into ARB drug products; reports on finding of a new nitrosamine impurity in certain lots of losartan and product recall

FDA provides update on ongoing investigation into ARB drugs; new losartan recall announced

Also Read:   Coronavirus (COVID-19) Update: FDA Issues First Emergency Authorization for Sample Pooling in Diagnostic Testing